Jan 8, 2012 1:35 PM PST
It is very gratifying that the first analyst initiates coverage of BioPorto, with a strong BUY recommendation and a price target of 16.7, ie. an upside of 125%.The analysis can be found by using google, seach" proinvestor +stock inition report"I was very positively...
| Upgrade |
Strong Buy |
| Long-Term |
Low |
Jun 21, 2011 12:30 PM PDT
FDA has accepted The Ngal test for review - 25 July 2011 http://www.bioporto.com/content/download/1970/45504/version/3/file/announcement+13+2011.pdf BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease...
| Upgrade |
Strong Buy |
| Mid-Term |
Low |
